Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders

References

• Baldessarini RJ. Chemotherapy in Psychiatry. third ed. New York: Springer Press; 2013.
   Google Scholar
• Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol ExpTher. 2010;334(1):171–181.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Riva MA. Preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Exp Opin Drug Discov. 2013;8(1):1297–1307.
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: systematic review of the published literature. Clin Pharmacokinetics. 2017;56(5):493–503.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Kimura T, Guarino J. Six-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5(6):322–331.
   PubMedGoogle Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–967.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: six-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–677.
   PubMed Web of Science ®Google Scholar
• Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: six-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519–530.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–836.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 and 160 mg/day in the treatment of schizophrenia: randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Res. 2013;145(1–3):101–109.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: 12-month, double-blind, noninferiority study. Schizophrenia Res. 2013;147(1):95–102.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: randomized, six-week, open-label study. J Clin Psychiatry. 2013;74(2):170–179.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507–515.
   PubMed Web of Science ®Google Scholar
• Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: 6-month, open-label, extension study. CNS Spectrums. 2014;19(4):330–339.
   PubMed Web of Science ®Google Scholar
• Correll CU, Cucchiaro J, Silva R, et al. Long-term safety and effectiveness of lurasidone in schizophrenia: 22-month, open-label extension study. CNS Spectrums. 2016;21(5):393–402.
   PubMed Web of Science ®Google Scholar
• Tandon R, Cucchiaro J, Phillips D, et al. Double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol. 2016;30(1):69–77.
   PubMed Web of Science ®Google Scholar
• Avila CC, Cabello M, Cieza A, et al. Functioning and disability in bipolar disorders: systematic review of literature using the ICF as a reference. Bipolar Disord. 2010;12(5):473–482.
   PubMed Web of Science ®Google Scholar
• Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry. 2011;16(12):1234–1246.
   PubMed Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531–535.
   PubMed Web of Science ®Google Scholar
• Goodwin G. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143–157.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.
   PubMed Web of Science ®Google Scholar
• Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II, and major depressive disorders. J Affect Disord. 2015;178(6):71–78.
   PubMedGoogle Scholar
• Vázquez GH, Holtzman JN, Tondo L, et al. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. 2015;183(9):258–262.
   PubMedGoogle Scholar
• Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–1262.
   PubMed Web of Science ®Google Scholar
• Vázquez GH, Tondo L, Undurraga J, et al. Overview of antidepressant treatment in bipolar depression: critical commentary. Intl J Neuropsychopharmacol. 2013;16(7):1673–1685.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: review of its use in bipolar disorder. Drugs. 2003;63(19):2029–2050.
   PubMed Web of Science ®Google Scholar
• Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–529.
   PubMed Web of Science ®Google Scholar
• Selle V, Schalkwijk S, Vázquez GH, et al. Treatments for acute bipolar depression: meta-analysis of placebo-controlled monotherapy trials of lithium, anticonvulsants, and antipsychotics. Pharmacopsychiatry. 2013;47(2):43–52.
   Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–177.
   PubMed Web of Science ®Google Scholar
• Suppes T, Kroger H, Pikalov A, et al. Lurasidone adjunctive with lithium or valproate for bipolar depression: placebo-controlled trial utilizing prospective and retrospective enrollment cohorts. J Psychiatr Res. 2016;78(7):86–93.
   PubMedGoogle Scholar
• Fornaro M, De Berardis D, Perna G, et al. Lurasidone in the treatment of bipolar depression: systematic review. Biomed Res Int. 2017;2017(5:3084859):1–17.
   Google Scholar
• McIntyre RS, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(4):398–405.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Forester BP, Tsai J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post-hoc analysis of two double-blind, placebo-controlled studies. J Clin Psychiatry. 2016;77(10):e1324–e1331.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Sarma K, Silva R, et al. Lurasidone in the long-term treatment of patients with bipolar disorder: 24-week open-label extension study. Depress Anxiety. 2016;33(5):424–434.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, MacFadden W, et al. Randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360.
   PubMed Web of Science ®Google Scholar
• Corya SA, Perlis RH, Keck PE, et al. 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006;67(5):798–806.
   PubMed Web of Science ®Google Scholar
• Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder With mixed features: randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400–407.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Mao Y, Pikalov A, et al. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30(6):342–350.
   PubMed Web of Science ®Google Scholar
• Vázquez CH, Lolich M, Cabrera C, et al. Mixed symptoms in mood disorders: systematic review. J Affect Disord. 2018;225(1):756–760.
   Web of Science ®Google Scholar